Insiders · SWTX

Daniel Lynch

Director at SpringWorks Therapeutics, Inc. (SWTX)

Daniel Lynch has filed 17 insider reports with the SEC since February 2021, as director at SpringWorks Therapeutics, Inc. (SWTX), director at 2seventy bio, Inc. (TSVT) and director at bluebird bio, Inc. (BLUE) and at 1 more company. Daniel Lynch made no open-market purchases or sales in the last 12 months. The latest filing, on July 2, 2025, reports sale back to the company at SpringWorks Therapeutics, Inc. (SWTX).

Filings
17
Companies
4
Bought on market
None
Sold on market
$12.4M

Companies where Daniel Lynch is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
SpringWorks Therapeutics, Inc. logo
SWTX
SpringWorks Therapeutics, Inc.
Director0$12.4MJul 2, 2025
2seventy bio, Inc. logo
TSVT
2seventy bio, Inc.
Director21,053Jun 15, 2023
bluebird bio, Inc. logo
BLUE
bluebird bio, Inc.
Director7,959Nov 17, 2021
Translate Bio, Inc. logo
TBIO
Translate Bio, Inc.
Director221,825Feb 16, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Daniel Lynch.

Compare Daniel Lynch with

Other insiders at the same companies

Questions about Daniel Lynch

What is Daniel Lynch's role at SpringWorks Therapeutics, Inc.?
Daniel Lynch reports to the SEC as director at SpringWorks Therapeutics, Inc. (SWTX), according to the latest filing on July 2, 2025. Daniel Lynch has also filed as director at 2seventy bio, Inc. (TSVT), director at bluebird bio, Inc. (BLUE) and director at Translate Bio, Inc. (TBIO).
How many shares does Daniel Lynch own?
After the latest filing that states it, Daniel Lynch directly owned 21,053 shares of 2seventy bio, Inc. (TSVT), 7,959 shares of bluebird bio, Inc. (BLUE) and 221,825 shares of Translate Bio, Inc. (TBIO). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Daniel Lynch bought or sold stock recently?
The most recent open-market sale was on February 20, 2025: sold 47,600 shares of SpringWorks Therapeutics, Inc. (SWTX) for $2.87M at an average of $60.22.
How do I get alerts when Daniel Lynch files?
Follow Daniel Lynch on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Daniel Lynch (SEC CIK 0001177082). Totals count each trade once, skipping amendments whose original is on file, from Feb 11, 2021 on. View on SEC EDGAR · Get this as JSON